» Articles » PMID: 32505416

Relation of Copeptin with Diabetic and Renal Function Markers Among Patients with Diabetes Mellitus Progressing Towards Diabetic Nephropathy

Overview
Journal Arch Med Res
Specialty General Medicine
Date 2020 Jun 8
PMID 32505416
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Arginine vasopressin (AVP) plays an important role in the pathophysiology of Diabetes Mellitus (DM) and its related complications like diabetic nephropathy. Copeptin is considered as a reliable surrogate biomarker of AVP. If raised levels of copeptin in diabetic patients are detected earlier, prognosis of DM can be improved by timely modulating the treatment strategy.

Aims Of The Study: The study is therefore planned to assess copeptin levels in different groups of DM and in healthy controls to suggest a better and reliable biomarker for progressive stages of DM.

Methods: Subjects were recruited as controls, pre diabetes, DM without nephropathy and diabetic nephropathy. Serum copeptin levels were measured by ELISA. While, Blood Urea Nitrogen (BUN), creatinine, Glycosylated Hemoglobin (HbA1c) and spot urinary albumin creatinine ratio (UACR) were done using spectrophotometry. Statistical analysis was done using ANOVA and Pearson's correlation tests on SPSS.

Results: The average copeptin levels were 215.096 pg/mL. Copeptin levels were significantly elevated in subjects with positive family history of DM (p = 0.025), levels were also raised in pre diabetes kpatients (252.85 pg/mL) as compared to other groups. Copeptin levels were also correlated with HbA1c r = 0.171 (p = 0.101), BUN r = 0.244 (p = 0.007), creatinine r = 0.215 (p = 0.018), UACR r = 0.375 (p = <0.001) and GFR r = 0.215 (p = <0.019).

Conclusion: The significant correlation of copeptin with diabetic and renal biomarkers, along with its positive association with family history of DM support its' role as an early and reliable biomarker of DM and its associated nephropathy.

Citing Articles

Diabetic vascular diseases: molecular mechanisms and therapeutic strategies.

Li Y, Liu Y, Liu S, Gao M, Wang W, Chen K Signal Transduct Target Ther. 2023; 8(1):152.

PMID: 37037849 PMC: 10086073. DOI: 10.1038/s41392-023-01400-z.


Review novel insights into the diagnostic and prognostic function of copeptin in daily clinical practice.

Wu P, Wang L, Su X, Wang B, Cheng Y Mol Biol Rep. 2023; 50(4):3755-3765.

PMID: 36662451 PMC: 9853489. DOI: 10.1007/s11033-023-08246-2.


Association between Copeptin and Metabolic Syndrome: A Systematic Review.

Rojas-Humpire R, Soriano-Moreno D, Galindo-Yllu B, Zafra-Tanaka J J Nutr Metab. 2022; 2022:5237903.

PMID: 36317191 PMC: 9617695. DOI: 10.1155/2022/5237903.


The role of copeptin in kidney disease.

Iglesias P, Silvestre R, Fernandez-Reyes M, Diez J Endocrine. 2022; 79(3):420-429.

PMID: 36242751 DOI: 10.1007/s12020-022-03219-0.


Effects of Huangqi Liuyi Decoction in the Treatment of Diabetic Nephropathy and Tissue Distribution Difference of its Six Active Constituents Between Normal and Diabetic Nephropathy Mouse Models.

Wang Q, Shi Y, Wu Z, Song X, Luo J, Yang H Front Pharmacol. 2022; 13:934720.

PMID: 35800436 PMC: 9253459. DOI: 10.3389/fphar.2022.934720.